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Sex-Related Differences in Myocardial Remodeling
Maddalena Piro, MD, PHD,* Roberta Della Bona, MD,* Antonio Abbate, MD, PHD,*†
Luigi M. Biasucci, MD,* Filippo Crea, MD*
Rome, Italy; and Richmond, Virginia
Sex has a profound impact on myocardial remodeling, which is defined as the molecular and cellular events af-
ter an injury to the myocardium (i.e., necrosis, pressure overload, volume overload, and aging) leading to a
change in shape, dimension, and function of cardiac chambers. Indeed, experimental studies and post-mortem
and observational clinical studies suggest the presence of important differences in myocardial remodeling be-
tween females and males in response to different types of injures including aging, pressure and volume over-
load, and myocardial infarction. Interestingly, the remodeling process appears to be more favorable in women
versus men; women are more likely to present heart failure with preserved systolic function and are at greater
risk for low output syndrome acutely. These differences between men and women are widely held to be related
to sex hormones such as estrogen, although the molecular effects of estrogen on ventricular cardiomyocytes are
incompletely understood. In this review, we summarize the evidence supporting these notions and discuss the
underlying mechanisms and the clinical implications. (J Am Coll Cardiol 2010;55:1057–65) © 2010 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.065A
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myocardial remodeling is defined as the molecular and
ellular events after an injury to the myocardium (i.e.,
ecrosis, pressure overload, volume overload, and aging)
eading to a change in shape, dimension, and function of
ardiac chambers. There are 2 patterns of remodeling:
oncentric and eccentric hypertrophy. The former is asso-
iated with an increase in wall thickness and initial preser-
ation of cavity size and ejection fraction (EF). The latter is
ssociated with progressive chamber dilation and dysfunc-
ion but with initial preservation of the stroke volume (1–3).
Sex has a profound impact on remodeling. Indeed,
bservational clinical studies and post-mortem and experi-
ental studies suggest the presence of important differences
n cardiac remodeling between females and males. In the
rst part of this review, we compare these differences in
pecific pathophysiological settings including aging cardio-
yopathy, pressure and volume overload, myocardial ische-
ia, cardiogenic shock, and diastolic heart failure. We have
ncluded post-mortem and clinical and experimental obser-
ations. In the second part of the review, we discuss the
lausible biological mechanisms responsible for sex-related
ifferences, including the effect of estrogen on vascular and
ardiac cell.
rom the *Catholic University of the Sacred Heart, Rome, Italy; and the †VCU
auley Heart Center, Virginia Commonwealth University, Richmond, Virginia. Dr.
iasucci is a consultant for Pfizer, Sanofi-Aventis, Roche Diagnostic, and Siemens
iagnostic, and receives grants from Sanofi-Aventis and Boehringer-Ingelheim.t
Manuscript received February 13, 2009; revised manuscript received July 27, 2009,
ccepted September 1, 2009.ging Cardiomyopathy
yocyte loss is the common final pathway leading to heart
ailure due to multiple causes, including aging. Aging
ardiomyopathy is a clinically recognized entity (4). In an
utopsy study, Olivetti et al. (5) analyzed the changes in
umber and size of ventricular myocytes in the hearts of 53
omen and 53 men (whose body weight was not 20% or
20% of the optimal weight for sex, height, and age), in the
ge interval from 17 to 95 years. Among autopsy criteria for
xclusion, they considered heart weight 400 g and 450 g
or women and men, respectively, severe atherosclerosis, and
cute and chronic myocardial infarction (MI). They demon-
trated that, while aging was associated with preservation of
ardiac weight and myocyte number and volume in females,
1 g/year of myocardium was lost in males, in association with
loss of 64 millions cells/year. Furthermore, myocyte cell
olume increased at rate of 158 m3/year in the left ventricle
LV) and 167 m3/year in the right ventricle in men but not
n women. Moreover, the fraction of mononucleated and
inucleated myocytes remained constant in the female heart
ith aging. In contrast, in men, mononucleated myocytes
ecreased by 0.3% per year in the LV and 0.2% per year in
he right ventricle, while the percent of binucleated myo-
ytes increased by 0.3% per year in the LV and 0.2% per year
n the right ventricle.
These findings support the notion that sex differences
ay play a significant role in the detrimental effect of aging
n the heart. In men, the progressive increase in average
yocyte cell volume probably represents a reactive hyper-rophic response to myocyte loss, thus preserving left and
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with aging. The basis for the
differential impact of aging on
the heart of males and females is
currently unknown. A potential
explanation may be related to the
higher cardiac work load of male
hearts throughout life, leading to
an attenuation of the growth re-
serve of the myocardium with
age in men (6–8). Moreover, sex
appears to be an important deter-
minant of the occurrence of ap-
optosis (9). Apoptosis, or pro-
grammed cell death, is the
principal form of chronic cell loss
(10). In a post-mortem study on
humans, Mallat et al. (11) found
that the apoptotic index was
3-fold higher in men than in
women free of any cardiovascular
disease who died of either violent
r natural causes. The lack of an increase in apoptosis rate
nd of a decrease in LV mass in the aging female heart
ight help to explain the reduced incidence of aging
ardiomyopathy in women as compared with men. This
ypothesis is in line with the findings by an animal study by
hang et al. (12) in monkeys (Macaca fascicularis). Old male
onkeys had a 4-fold increase in frequency of apoptosis
ompared with old female monkeys without any increase in
roliferation-capable myocyte as assessed by Ki-67 expression.
yocardial Response to Pressure Overload
ressure overload is a common cause of cardiac remodeling
nd heart failure. Villari et al. (13) demonstrated a positive
yocardial remodeling and a decrease in muscle mass in 15
atients who underwent aortic valve replacement. Subse-
uently, Morris et al. (14) attempted to characterize sex
ifferences in recovery of ventricular function and survival
fter aortic valve replacement. Women showed an earlier
mprovement than men in EF after aortic valve replacement
uggesting that sex-related factors may influence the adap-
ive response of the LV to pressure overload.
In line with these studies, Kostkiewicz et al. (15) studied
95 patients with isolated severe aortic stenosis at echocar-
iography to investigate the influence of sex on LV remod-
ling and preservation of systolic function. When compared
ith men, women had similar transvalvular aortic gradient
nd estimated aortic area, but had a greater degree of left
entricular hypertrophy (LVH) documented as changes in
V geometry (increased LV mass, increased relative wall
hickness, and smaller end-diastolic and -systolic dimen-
ions) and had preserved LV function (greater LV fractional
hortening and EF), in keeping with the results of other
Abbreviations
and Acronyms
ANF  atrial natriuretic
factor
EF  ejection fraction
EPC  endothelial
progenitor cell
ER  estrogen receptor
IGF  insulin growth factor
LV  left ventricle/
ventricular
LVH  left ventricular
hypertrophy
MI  myocardial infarction
mRNA  messenger
ribonucleic acid
MSC  mesenchymal
stem cell
SHR  spontaneously
hypertensive rattudies (16–20). wWhether these differences result from intrinsic differences
n molecular adaptation to pressure overload between men
nd women or are related to other factors extrinsic to the
yocardium is unknown. Differences in geometric remod-
ling and an earlier onset of impaired systolic pump perfor-
ance in male versus female animals have also been re-
orted by Pfeffer et al. (21) in a spontaneously hypertensive
at (SHR), a model of pressure overload cardiomyopathy.
hen compared with male SHR, female SHR had greater
F and cardiac index and smaller end-diastolic and -systolic
olumes, despite similar systolic blood pressure values.
emale SHR (ages 6 to 18 months) had normal heart
imensions and function whereas male SHR had LV
ysfunction and heart failure by 12 months.
Using banding of the transverse aorta as another model of
ressure overload in male and female Wistar rats, Weinberg
t al. (22) examined LV contractile reserve in the isolated
eart 6 weeks after banding. Higher pressures (contractile
orce) developed in females than in males. Despite a similar
egree of LVH and systolic wall stress, female hearts had
reserved contractile reserve, whereas male hearts had de-
ressed contractile reserve. The expression of -myosin
eavy chain and messenger ribonucleic acid (mRNA) of
trial natriuretic factor (ANF) in the ventricular myocar-
ium was greater in male than in female hearts. Conversely,
arcoplasmic reticulum Ca-adenosine triphosphatase
RNA levels were depressed in male rats but not in female
ats, compared with control rats. Thus, this study for the
rst time demonstrated that there are striking sex-related
ifferences in the expression of key genes known to play
ritical roles in cardiac calcium regeneration and contractile
unction at an early stage of chronic pressure overload before
he development of overt failure. In this animal model, the
eduction in contractile reserve observed in male LVH rats
ay be explained in part by the greater up-regulation of
eavy -myosin, normally expressed in animal fetal life and
own-regulated in the post-natal LV (23), and by the lower
xpression of sarcoplasmic reticulum Ca-adenosine
riphosphatase, closely related to excitation-contraction
oupling (24). Moreover, the removal of sex hormones by
onadectomy in rats significantly reduces cardiac function
nd induces a shift in myosin heavy chain content to the
lower isoform (V3/), indicative of a pathological shift that
an be reversed by hormonal supplementation (25). These
henomena might play an important role also in humans,
ut this hypothesis has not specifically been tested.
yocardial Response to Volume Overload
olume overload leads to eccentric hypertrophy and eventually
o heart failure. A clinical study by Rohde et al. (26) demon-
trated that, in comparison with men, women with isolated
ortic regurgitation had smaller end-diastolic and -systolic
olumes, despite a similar degree of regurgitation. Multivariate
nalysis showed that female sex was independently associated
ith a greater LV mass/volume ratio after adjusting for the
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March 16, 2010:1057–65 Sex and Myocardial Remodelingeverity of the valvular lesion, age, LV function, and concom-
tant bypass graft surgery. The LV mass and volume were
alculated based on the criteria defined by Devereux and
eichek (Penn convention) (26), and adjusted for body surface
rea.
Additional evidence supporting the presence of sex-
elated differences in LV adaptation to volume overload
erives from an animal study by Gardner et al. (27). They
emonstrated that female rats adapt more favorably to
olume overload induced by an infrarenal aortocaval fistula
han do male rats. Female hearts developed concentric
ypertrophy with no impairment of cardiac function, min-
mal ventricular dilation, and no changes in myocardial
ompliance after 8 weeks of fistula creation. In contrast,
ale hearts had significant fistula-induced dilation and
ecreased ventricular compliance. Moreover, the mortality
ate was 10-fold higher for males than for females (25% vs.
%), despite a similar degree of volume overload. The main
ifference between male and female hearts was not in the
egree of hypertrophy, but rather in the degree of dilation.
hese findings suggest that in the presence of volume
verload, female hearts develop appropriate concentric hy-
ertrophy sufficient to maintain a stable compensated state,
reventing the development of ventricular dilation and heart
ailure.
yocardial Response to
cute Myocardial Ischemia
fter acute coronary occlusion, the ensuing myocardial
schemia leads to excitation-contraction uncoupling, cell
dema, apoptosis, and necrosis. Cardiomyocyte ischemic
ecrosis peaks at 24 h. Apoptosis peaks earlier (6 h), while
eing present also late after the index event, contributing to
dverse remodeling (10). Unfavorable myocardial remodel-
ng is a common consequence of acute MI (1). Heart failure
s more frequent and severe among men than among
omen. In the CHARM (Candesartan in Heart failure:
ssessment of Reduction in Mortality and Morbidity) trial,
omen presenting with heart failure symptoms had higher
VEF and, after adjustment for all baseline characteristics,
ad better overall survival versus men, independent of
enopause status (28).
Sex-related differences in cardiac remodeling are probably
mong the explanations of such sex-related differences in
linical outcome (29). Post-mortem data suggest that males
nd females may have a different modulation of the apop-
otic pathway in the peri-infarct region. Females appear to
e, at least partially, protected from ischemia-induced acti-
ation of the apoptotic cascade. Biondi-Zoccai et al. (9)
howed that, among patients who died late after acute MI,
ales had a 10-fold higher apoptotic rate than women in
eri-infarct region and greater bax expression than women
n the peri-infarct region. These findings may explain the
ore aggressive course of post-infarction heart failure in
en and its relatively more benign course in women. Guerra mt al. (29) found that apoptotic and necrotic myocyte death
ate differed in the failing hearts of women and men. The
ower rate of cell death in women was associated with a
onger duration of the cardiomyopathy, a later onset of
ardiac decompensation, and a longer interval between heart
ailure and transplantation.
In an animal model of experimental MI by Cavasin et al.
30), male mice, compared with female, had delayed myo-
ardial healing, higher infarct expansion index, and a greater
ncidence in cardiac rupture. During the chronic phase of
ost-MI (12 weeks after induction of MI), the male
urvivors had worse cardiac function and more pronounced
aladaptive remodeling, including a significantly greater
ilation and myocyte hypertrophy. In contrast, females had
times lower mortality despite similar infarct size and
howed a better outcome during the development of heart
ailure. The sex-related differences in early mortality and in
ardiac rupture occurring during the first week post-MI may
e attributable to differing mechanisms of infarct healing,
issue repair, degradation of the extracellular matrix, and
yocyte slippage. In fact, male mice compared with female
ice had premature extracellular matrix degradation, be-
ause of the higher number of neutrophils and increased
ctivity of metalloproteinases, and they had a delayed
emoval of necrotic tissue and scar formation, probably
elated to the lower number of macrophages (30).
ardiogenic Shock and “Diastolic” Heart Failure
he reduced ventricular dilation during remodeling in
omen compared with men, especially in the acute setting,
ay be beneficial on the one hand yet detrimental on the
ther. Indeed, an initial mild ventricular dilation during an
cute insult (i.e., acute MI, acute myocarditis, and so forth)
ay be protective because it helps maintain an adequate
troke volume. In a study on patients presenting with shock,
omen had a significantly lower cardiac index despite
imilar LVEF. Moreover, women with cardiogenic shock
omplicating acute MI have more frequent adverse clinical
vents and mechanical complications (31). Low cardiac
utput syndrome after cardiac surgery is also more common
mong women (32).
The reduced ventricular dilation during remodeling in
omen compared with men helps explain why approxi-
ately one-half of women presenting with heart failure
ymptoms have preserved LVEF versus one-third of men
33). When affected by heart failure, women are also more
ikely than men to present with congestive symptoms (34).
n an elegant study, Regitz-Zagrosek et al. (35) showed that
omen with heart failure and preserved LVEF had signif-
cantly greater impairment in diastolic filling compared with
en. Both men and women with diastolic dysfunction and
reserved EF showed an increase in the ventricular end-
iastolic pressure-volume relation. When compared with
en, women with heart failure and preserved systolic
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Sex and Myocardial Remodeling March 16, 2010:1057–65unction had smaller LV end-diastolic volume and stroke
olumes but higher LV end-diastolic pressure.
ole of Estrogens In Myocardial Remodeling
he observed sex differences in heart disease, and particu-
arly in ventricular remodeling, have led to considerable
peculation regarding the underlying etiology, in which the
ole of circulating sex hormones must be certainly consid-
red. Although the specific mechanisms by which estrogens
xert their cardioprotective effects are not completely un-
erstood, they include indirect and direct effects of estrogens
n vascular and cardiac cells.
strogens and menopause. It is well established that the
reat majority of women present with heart failure after
enopause, when circulating levels of estrogen are low.
hus, the question is how estrogens can be protective after
he menopause. In this regard, it is worth noting that it is
ndeed important to distinguish between ovarian synthesis
f estrogens, which is subject to dramatic changes during
he course of life, in particular after menopause, and
ntramyocardial synthesis, which is less influenced by such
ariations (36). Moreover, functional estrogen receptors
ERs [ and ]) have been demonstrated in ventricular
yocardium of both males and females, and estrogen
inding has both genomic and nongenomic effects (37).
strogen binding has genomic effects as ERs are ligand-
ctivated transcription factors and can activate transcription
f a number of genes whose promoter regions contain
andem estrogen response elements (38). Conversely, ERs
ediate nongenomic effects, inducing intracellular-
ignaling cascades, such as activation of protein kinase C
nd extracellular signal-regulated kinase, and modulating
ignaling by growth factors such as insulin-like growth
actor (IGF)-1, epidermal growth factor, or transforming
rowth factor (39). In an animal model, Novotny et al. (40)
emonstrated for the first time a protective role for non-
enomic ER signaling in the aged female rat heart. In
articular, acute ER activation was effective in reducing
schemic-reperfusion injury and necrotic and/or apoptotic
ell death in the aged heart, which could have clinical
elevance for selective ER modulators as potential thera-
eutic targets in the aging female (40).
Probably, in post-menopausal women an up-regulation of
ongenomic ER signaling might contribute to explain sex
ifferences in myocardial remodeling. Moreover, it should
e considered that in the absence of estrogens, ERs can be
ecruited to transactivate estrogen-responsive genes. For
xample, IGF-1–induced transcription is dependent on the
ecruitment of ER to the activator protein 1 complex but
oes not require estrogen to be present (41).
etabolic and vascular effects of estrogens. Estrogens
re known to exert beneficial effect on lipid metabolism and
ther endocrine effects that indirectly can regulate myocar-
ial adaptation. Moreover, their protective role on modula- mion of proinflammatory cytokines (42) and cardiac fibro-
last growth (43) is well known.
Estrogens have also been demonstrated to exert their
rotective action on vascular and myocardial cells, both
irectly and through receptor-mediated effects. It has been
emonstrated that estrogens directly relax coronary arteries
44) and restore endothelial function of peripheral resistance
rteries in normotensive and hypertensive post-menopausal
omen (45) through mechanisms involving release of nitric
xide. Cardiac myocytes and cardiac fibroblasts also express
unctional ER and , and this activation downstream
argets genes that play a key role in LVH, myocyte survival,
nd apoptosis (46).
strogens and LVH. Van Eickels et al. (47) demonstrated
hat greater LVH developed in female ovariectomized mice
n a model of pressure overload than ovariectomized mice
ith replacement of physiological levels of 17-estradiol.
hey also observed a more pronounced ventricular expres-
ion of ANF in the banded, estrogen-supplemented group
han in the banded, vehicle-treated animals. In line with
hese findings, to elucidate the underlying molecular mech-
nisms, the same group studied the relationship between
strogen antagonism of hypertrophy, ANF expression, and
uanylil cyclase A receptor signaling in cultured cardiomy-
cytes (48). They demonstrated that estrogen exerts pro-
ound antihypertrophic effects on ventricular myocytes, by
ransactivation of the ANF gene. Estrogen-induced ANF
ccumulation in the ventricular myocyte most likely results
n ANF receptor activation in an autocrine/paracrine man-
er, which in turn evokes cytoplasmic cyclic-guanosine
onophosphate signaling downstream of the guanylil cy-
lase A receptor. In summary, estrogen-mediated ANF
nduction in cardiac hypertrophy contributes to reduce
VH.
strogens and apoptosis. Another molecular mechanism
roven to reduce cytopathic damage associated with myocar-
ial injury involves the activation of the serine/threonine
rotein kinase called Akt (also known as protein kinase B) that
egulates a broad range of physiological responses including
etabolism, gene transcription, and cell survival (49).
The activation of Akt in a sex-dependent manner may help
xplain different susceptibility to cardiovascular disease and
upport the beneficial role of estrogen stimulation (Fig. 1).
amper-Kirby et al. (50) demonstrated that adult pre-
enopausal women display a significantly greater frequency of
taining of Akt1/2 (phopsho-Ser473/474) in the nuclei of their
ardiac myocytes than do men or post-menopausal women.
hese differences have also been seen in transgenic mice that
pecifically overexpress IGF-1, a proven stimulus for Akt
ctivation, in the heart. In fact, both localization of phospho-
kt in myocardial nuclei and Akt kinase activity are increased in
uclear extracts from sexually mature female mice versus males.
oreover, they demonstrated an increased cytosolic localiza-
ion of phospho-forkhead, a downstream nuclear target of Akt,
n myocytes of female mouse hearts compared with maleouse hearts (50). This finding is in agreement with a greater
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March 16, 2010:1057–65 Sex and Myocardial Remodelingegree of Akt phosphorylation and activation in female heart
nd illustrates a potential key sex-related difference in Akt-
ssociated cardiac signaling.
In support of a role for estrogen in promotion of Akt
ignaling, exposure of rat cardiac myocyte cultures to 17-
stradiol or phytoestrogen genistein increased nuclear stain-
ng for Akt1/2 (phospho-Ser 473/474) and cytoplasmatic
taining for phospho-forkhead (phospho-Ser 256) (51).
oreover, in line with the impact of phytoestrogen on Akt
ignaling, it has been reported that soy-based diets may
ffect the cardiovascular phenotypes in rats, playing a
ardioprotective role in ischemia-reperfusion injury and in
ntihypertensive effects (52).
Estrogen-induced Akt activation could protect females
gainst cardiovascular disease by increasing the resistance of
heir cardiomyocytes to cytotoxic stimuli.
Akt plays a central role in cell survival, modulating both
he mitochondrial and the receptor-mediated pathway of
poptotic cascade (53). Akt-induced Bad phosphorylation
romotes retention of Bad in the cytoplasm and prevents
nitiation of the mitochondrial pathway of apoptosis, reduc-
ng Bad inhibition of the antiapoptotic actions of Bcl-2 and
cl-X (54). Moreover, Akt phosphorylates and inhibits
aspase-9, which is responsible for activation of caspase-3
Figure 1 Activation of Akt in a Sex-Dependent Manner
The activation of Akt in a sex-dependent manner may help explain different suscep
tion. Akt1/2 is overexpressed in the nuclei of the cardiac myocytes of adult pre-m
inducing Bad phosphorylation, reducing Bad inhibition of the antiapoptotic actions
caspase-3 and for degradation of cellular macromolecules results; inhibits the rec
ily of transcription factors, inhibiting them to drive expression of Fas ligand (Fas L)
and to ischemia-reperfusion injury. In myocytes of female hearts, there is an incre
growth factor (IGF)-1, a proven stimulus for Akt activation. Estrogen increases nucl
induces the phosphorylation of the IGF-1 receptor on myocytes, improving cell surv
and Bcl-X, and decreasing the induction of proapoptotic proteins, such as Bax. Es
and inflammatory responses, increasing the cellular resistance to cytotoxic stimulind for degradation of cellular macromolecules results (49). ekt also inhibits the receptor-mediated pathway of apopto-
is by phosphorylating members of the forkhead family of
ranscription factors, causing them to be retained in the
ytoplasm and inhibiting them to drive expression of Fas
igand (55).
Increased phospho-forkhead levels, which have been
inked to antiapoptotic effects, could account for decreased
poptosis in female failing heart relative to male hearts.
Furthermore, Akt promotes glycogen synthesis that
ay itself increase resistance to cellular hypoxia during
schemia, providing a greater pool of reserve for anerobic gly-
olysis (53) and inducing cardioprotection from ischemia-
eperfusion injury, as described in ovariectomized rats (56).
inally, the sex-related differences in Akt activity could be
ssociated with a functional link among estrogen status, Akt
ctivation, and cytoprotection at the level of the isolated
ardiomyocytes. Convergent signaling of different pathways on
kt probably reflects important cross-talk between signal trans-
uction mechanisms, as it has been described for estrogen-
ediated stimulation of the IGF-1 receptor pathway and
ctivation of the IGF-1 receptor by estrogen-mediated stimu-
ation of phosphatidil-inositol-triphosphate-kinase/Akt (57).
n fact, estrogen is able to phosphorylate IGF-1 receptor on
yocytes, improving cell survival (58), indirectly enhancing the
to cardiovascular disease and support the beneficial role of estrogen stimula-
usal women. Akt prevents initiation of the mitochondrial pathway of apoptosis
-2 and Bcl-X; phosphorylates and inhibits caspase-9, responsible for activation of
ediated pathway of apoptosis by phosphorylating members of the forkhead fam-
promotes glycogen synthesis that may increase the resistance to cellular hypoxia
ytosolic localization of phospho-forkhead, and an overexpression of the insulin
aining for Akt1/2 and cytoplasmatic staining for phospho-forkhead. Moreover, it
directly enhancing the expression of antiapoptotic gene products, such as Bcl-2
and IGF-1 stimulate nitric oxide, which promotes vasodilation and antithrombotic
 endothelial nitric oxide synthase; OE  estrogen.tibility
enopa
of Bcl
eptor-m
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ased c
ear st
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. eNOsxpression of antiapoptotic gene products, such as Bcl-2 and
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Sex and Myocardial Remodeling March 16, 2010:1057–65cl-x, and decreasing the induction of proapoptotic proteins,
uch as Bax (59). Moreover, estrogen and IGF-1 stimulate
itric oxide, which promotes vasodilation and antithrombotic
nd inflammatory responses (60), increasing the cellular resis-
ance to cytotoxic stimuli.
strogens and stem cells. As shown in the preceding text,
emale patients show relative cardiac protection from acute
nfarction and better outcome after MI compared with
ales (61). Such sex dimorphisms may also be related
ecause of the facilitating effect of estrogens on mobilization
f endothelial progenitor cells (EPCs), which appear to
ontribute to the preservation of cardiac function after acute
I (62). The ER seems to play a more prominent role in
his process (63). For the first time, Hamada et al. (62)
emonstrated in a murine model that physiological levels of
stradiol up-regulate ER mRNA in EPCs, indicating that
he ligand has potent effects on the expression of its own
eceptor (62).
Moreover, ER contributes to up-regulation of vascular
ndothelial growth factor. It has been postulated that 17-
stradiol may also mobilize EPCs through endothelial nitric
xide synthase-mediated activation of matrix metalloproteinase-9
64). Up-regulation of matrix metalloproteinase-9 results in the
elease of soluble Kit ligand, which facilitates the transfer of
ndothelial cells from the quiescent to the proliferative pool
65). Interestingly, treatment with 17-estradiol significantly
ncreases the number of EPCs in spontaneously hypertensive
ats and delays senescence while augmenting telomerase activ-
ty in EPCs through the phosphatidil-inositol-triphosphate-
inase/Akt pathway (66,67). These data from an animal model
re in concordance with the results deriving from a human
tudy that demonstrated that women with higher plasma
strogen concentration showed a significantly higher level of
irculating EPCs (68). The increase in the number of EPCs by
7-estradiol has been demonstrated to be mediated by a
ecreased rate of apoptosis through a caspase-8–dependent
athway (69). Finally, these data provide additional evidence of
he importance of bone marrow–derived EPC phenotype in
schemic tissue repair.
Estrogens may exert an important influence on myocar-
ial remodeling after ischemic injury, partially through
aracrine growth hormone production by both EPC and
one marrow mesenchymal stem cells (MSC). In keeping
ith the hypothesis that sex differences exist in activated
SC function, Crisostomo et al. (70) demonstrated that
ipopolysaccharide- and hypoxia-induced vascular endothe-
ial growth factor production was significantly greater in
emale MSC compared with male MSC. Moreover, female
SC expressed significantly less pro-inflammatory cyto-
ines, tumor necrosis factor- and interleukin-6, compared
ith male MSC in response to acute lipopolysaccharide and
ypoxia, suggesting their ability to limit inflammatory
eactions (70). Moreover, stimulation of cardiac fibroblast
ith 17-estradiol induces nuclear translocation of ER
rotein, playing an important inhibitory role on renin-
ngiotensin system gene expression, and preventing fibro- plast proliferation, synthesis of collagen types I and III, and
xpression of 1 integrins (46,71).
Sex-related differences in signal transduction pathway
ay be associated with a greater resistance to hypoxia-
nduced stress in females versus males (72). Therefore, a
etter understanding of sex hormone regulation from a cell
iology perspective will be critical in improving patient
utcomes.
ole of Testosterone in Myocardial Remodeling
hether estrogen alone is cardioprotective in humans needs
o be clarified. Indeed, the observed sex differences and the
ncreased incidence of cardiac events among women after
enopause might not entirely be due to the depletion of
strogen, but might also be related to testosterone, as
ost-menopausal ovaries produce significant amount of
ndrogens in the form of testosterone and androstenedione
73). A positive correlation has been demonstrated in
ost-menopausal women between increased testosterone
evels and hypertension, decreased high-density lipoprotein
evels, impaired vascular reactivity, cardiac hypertrophy, and
oronary artery disease (74). For the first time in a mouse
odel of MI, Cavasin et al. (75) demonstrated that estrogen
nd testosterone play different and opposing roles in the
evelopment of heart failure and long-term remodeling
fter MI. In particular, estrogens (either endogenous or
upplemental) prevent maladaptive chronic remodeling and
urther deterioration of cardiac performance, whereas tes-
osterone (either endogenous or supplemental) adversely
ffects myocardial healing (as indicated by a higher rate of
ardiac rupture), promotes cardiac dysfunction and remod-
ling, and exerts pronounced effects when estrogen levels are
educed. However, it should be observed that plasma
strogen and testosterone levels in males and females who
eceived hormone replacement were much higher than
hysiological levels.
onclusions
he incidence and severity of cardiovascular diseases among
re-menopausal women is lower than among men of com-
arable age, even after correction for various risk factors
Table 1). The causes of this difference are unclear. Cardio-
ascular factors strongly associated with sex include vascular
unction (endothelium-dependent flow-mediated dilation
nd aortic compliance are greater in females) and an LV
ass index that is greater in males. After menopause, the
ates of cardiovascular diseases converge, and once affected
y ischemic heart disease, females may have a worse
rognosis than their male counterparts. The differences of
usceptibility are widely held to be related to sex hormones,
uch as estrogen, that exert potential benefit in inhibiting
he progression of cardiac disease. Estrogen’s ability to
nduce systemic vasodilation is in agreement with the
ypothesis that sex differences in cardiac disease may de-
end on the properties of the vascular wall as well as on the
c
o
C
p
v
c
c
ntricle/
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March 16, 2010:1057–65 Sex and Myocardial Remodelingardiac myocytes, even if the molecular effects of estrogen
n ventricular cardiomyocytes are less well understood.
onsidering the lower rates of cell loss associated with
Factors Influencing Cardiovascular Prognosis inTable 1 Factors Influencing Cardiovascular
Women
Aging Ca
Preservation of cardiac weight
Preservation of myocyte number
Preservation of myocyte volume
Constant mononucleate/binucleate myocytes ratio
Low apoptotic index
Increased apoptotic rate
Myocardial Respon
Earlier improvement in EF after aortic valve replacement
Greater degree of LVH
Increased LV mass
Increased relative wall thickness
Smaller end-diastolic and -systolic dimensions
Preserved LV function
Later onset of impaired systolic pump performance
Greater EF
Greater cardiac index
Smaller end-diastolic and -systolic volumes
Higher expression of -myosin heavy chain
Higher expression of ANF mRNA
Myocardial Respo
Smaller end-diastolic and -systolic volumes
Greater LV mass/volume ratio
Concentric hypertrophy
No impairment of cardiac function
Minimal ventricular dilation
No changes in myocardial compliance
Myocardial Response to
Lower apoptotic rate in peri-infarct region
Lower bax expression in peri-infarct region
Longer duration of the cardiomyopathy
Later onset of cardiac decompensation
Longer interval between heart failure and transplantation
Earlier myocardial healingd
Lower infarct expansion index
Three times lower mortality
Better cardiac function
Better remodeling
Cardiog
Significantly lower cardiac index
More frequent adverse clinical events
More frequent mechanical complications
More common low cardiac output syndrome
Hea
Preserved LV EF
Smaller LV end-diastolic volume
Smaller stroke volumes
Higher LV end-diastolic pressure
More frequent congestive symptoms
Greater impairment in diastolic filling
Data from animal studies are reported in italics.
ANF  atrial natriuretic factor; EF  ejection fraction; LV  left ve
ribonucleic acid.reservation of cardiac function and dimensions in females fersus males, it is not surprising that women presenting with
ongestive heart failure are likely to present with different
linical manifestations and significant differences in cardiac
en and Menosis in Women and Men
Men
yopathy
Reduction in cardiac weight (1 g/yr)
Reduction in myocyte number (64 million/yr)
Increase in myocyte cell volume
Decreased mononucleate/binucleate myocytes ratio
Apoptotic index 3-fold higher than women
Decreased apoptotic rate
Pressure Overload
Later improvement in EF after aortic valve replacement
Lower degree of LVH
Impaired LV function
Earlier onset of impaired systolic pump performance
Lower expression of -myosin heavy chain
Higher expression of ANF mRNA
Volume Overload
Larger end-diastolic and -systolic volumes
Lower LV mass/volume ratio
No concentric hypertrophy
Impairment of cardiac function
Significant ventricular dilation
Decreased ventricular compliance
e Myocardial Ischemia
10-fold higher apoptotic rate in peri-infarct region
Greater bax expression in peri-infarct region
Shorter duration of the cardiomyopathy
Earlier onset of cardiac decompensation
Shorter interval between heart failure and transplantation
Delayed myocardial healing
Higher infarct expansion index
Greater incidence in cardiac rupture
Worse cardiac function
Maladaptive remodeling
Significantly greater dilatation
Myocyte hypertrophy
Premature extracellular matrix degradation
Higher number of neutrophils
Increased activity of metalloproteinases
Shock
Higher cardiac index
Less frequent adverse clinical events
Less frequent mechanical complications
Less common low cardiac output syndrome
ure
Impaired LV EF
Greater LV end-diastolic volume
Greater stroke volumes
Lower LV end-diastolic pressure
Less frequent congestive symptoms
Lower impairment in diastolic filling
ventricular; LVH  left ventricular hypertrophy; mRNA  messengerWomProgn
rdiom
se to
nse to
Acut
enic
rt Failunction.
a
c
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a
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1
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1
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2
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Sex and Myocardial Remodeling March 16, 2010:1057–65Regardless of age and menopause, the remodeling process
ppears to be more favorable in women versus men. In
ontrast, women are more likely to present with “diastolic-
nly” dysfunction and are at greater risk for low output
yndrome acutely. Lower awareness of heart disease among
omen is likely responsible for the worse outcome observed
or women in some clinical series, and being a correctable
ssue, increased awareness of heart disease among women
hould still represent our number 1 priority.
Further, it is important to stress that being male or female
s a variable that should be dealt with in both basic science
nd clinical research. It is clear that the response of humans
nd animals to various disease states can be profoundly
ffected by sex. These differences are unlikely to be due only
o sex hormones. Indeed, some genes on the X chromosome
re expressed at higher levels in females than in males,
espite the process of X chromosome inactivation (76).
oreover, males express genes on the Y chromosome that
re absent in females. Thus, a better understanding of the
rocesses leading to differences in remodeling in women will
ost likely open the way to novel treatment modalities and
ltimately benefit patients of both sexes.
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